Compounds > perfosfamide
Page last updated: 2024-08-23

perfosfamide and paclitaxel

perfosfamide has been researched along with paclitaxel in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's1 (20.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Aebi, S; Fink, D; Haas, M; Howell, SB; Kim, HK; Nebel, S; Norris, PS1
Aebi, S; Fink, D; Fink, JL; Gordon, R; Howell, SB; Kim, HK; Zheng, H1
Bocci, G; Kerbel, RS; Nicolaou, KC1
Haskova, P; Jansova, H; Kalinowski, DS; Machacek, M; Potuckova, E; Richardson, DR; Richardson, V; Simunek, T; Tichotova, L; Vavrova, A1
Dziegiel, P; Jablonska, K; Maciejczyk, A; Matkowski, R; Partynska, A; Suchanski, J; Szymczak-Kulus, K; Ugorski, M; Urbaniak, A1

Other Studies

5 other study(ies) available for perfosfamide and paclitaxel

ArticleYear
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells.
    British journal of cancer, 1998, Volume: 77, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Cell Separation; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; DNA Repair; DNA, Neoplasm; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Melphalan; Paclitaxel; Tamoxifen; Thioguanine; Tumor Cells, Cultured; Tumor Stem Cell Assay

1998
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carrier Proteins; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; DNA Adducts; DNA Damage; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Fluorouracil; Humans; Melphalan; Methylnitronitrosoguanidine; Mutagenesis; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Thioguanine; Tumor Cells, Cultured

1997
Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.
    Cancer research, 2002, Dec-01, Volume: 62, Issue:23

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Bridged-Ring Compounds; Cell Division; Cell Survival; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Endothelium, Vascular; Epothilones; Humans; Paclitaxel; Tumor Cells, Cultured

2002
Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Aldehydes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cyclophosphamide; Deferoxamine; Doxorubicin; Drug Synergism; Fluorouracil; Humans; Hydrazones; Iron Chelating Agents; MCF-7 Cells; Methotrexate; Paclitaxel; Tamoxifen; Thiosemicarbazones

2014
Prolactin-induced protein (PIP) increases the sensitivity of breast cancer cells to drug-induced apoptosis.
    Scientific reports, 2023, 04-21, Volume: 13, Issue:1

    Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Female; Glycoproteins; Humans; Membrane Transport Proteins; Mice; Paclitaxel; Prolactin

2023